Arqule, Inc.

Daiichi Sankyo Company, Limited

Other

Daiichi Pharmaceutical Co., Ltd.

Shin Iimura

Mark Anthony Ashwell

Jean-Marc Lapierre

Yanbin Liu

Rocio Palma

Akihisa Matsuda

David Vensel

Anton Filikov

Steffi Koerner

Jason J Hill

Manish Tandon

Nivedita Namdev

Robert B Nicewonger

Chris Brassard

Kenichi Yoshida

Atsushi Nakayama

Nobuo Machinaga

Jun Chiba

Yoshiyuki Yoneda

Takanori Yamazaki

Takeshi Isoyama

Rie Miyauchi

Takahiro Kitamura

Yuko Yamamoto

Masatoshi Nagamochi

Sunanda Ghosh Dastidar

Ashwani Kumar Verma

Masayuki Ishizaki

Punit Kumar Srivastava

Kumaragurubaran Nagaswamy

Takeshi Murata

Yogesh Balasaheb Khairnar

Pramod Raosaheb Markad

Sonali Nanasaheb Pansare

Pradip Balu Wagh

Rijwan Jaffer Momin

Aniruddha Mondal

Balkrishna Ramchandra Kale

Soma Ghosh

Lalima Sharma

John J Baldwin

Toshiyuki Watanabe

Edward McDonald

Christopher Ronald Sarko

Sudharshan Eathiraj

Kevin Joseph Moriarty

Yuichi Sugimoto

Fumihito Muro

Akiko Shiina

Hideko Hoh

Robert Nicewonger

Jason Hill

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R, Rand Rare as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

Heterocyclic compounds as protein kinase inhibitors

The present invention relates to substituted imidazopyridinyl-aminopyridine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazopyridinyl-aminopyridine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Substituted imidazopyridinyl-aminopyridine compounds

The present invention relates to substituted imidazopyridinyl compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazopyridinyl compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Substituted imidazopyridinyl compounds

The present invention relates to substituted benzo[f]imidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo[f]imidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein Rrepresents a hydrogen atom or a C1-8 alkyl group; Rrepresents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, or a benzyloxy group which may be substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group which may be substituted; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and Arepresents a nitrogen atom or C&#x2014;R(wherein Rrepresents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group),

VLA-4 inhibitory drug

The present invention relates to a compound represented by the following formula (I): (wherein, W represents W-A-W- (in which, Wis substituted or unsubstituted aryl, etc., Ais &#x2014;NR&#x2014;, single bond, &#x2014;C(O)&#x2014;, etc., and Wis substituted or unsubstituted arylene, etc.), R is single bond, &#x2014;NH&#x2014;, &#x2014;OCH&#x2014;, alkenylene, etc., X is &#x2014;C(O)&#x2014;, &#x2014;CH&#x2014;, etc., and M is, for example, the following formula: (in which, R, Rand Reach independently represents hydrogen, hydroxyl, amino, halogen, etc., Ris hydrogen or lower alkyl, Y represents &#x2014;CH&#x2014;O&#x2014;, etc., Z is substituted or unsubstituted arylene, etc., Ais single bond, etc, and Ris hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VLA-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.

Vla-4 inhibitors

VLA-4 inhibitor compounds

Growing community of inventors

Tokyo, Japan

Shin Iimura